Indirect ELISA Assay Explained

Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Indirect ELISA Assay Explained

Sector: Diagnostics
YouTube video thumbnail

The indirect ELISA assay is a powerful and flexible method for detecting antibodies using enzyme linked immunoassay techniques. In this Bio Break episode, Nick and Nigel walk through how indirect ELISA works, why it uses two antibodies instead of one, and when this approach makes the most sense in real diagnostic workflows.

To start, indirect ELISA builds on concepts introduced in direct ELISA detection. You still begin with an antigen immobilized on a surface. However, instead of linking an enzyme directly to the primary antibody, indirect ELISA adds an extra detection step. This additional layer creates more options for what you can measure.

How Indirect ELISA Works

In an indirect ELISA assay, the first antibody binds directly to the antigen. This primary antibody has two important regions. One region recognizes the antigen, while the conserved region identifies it as an antibody. Next, a second antibody is introduced. This secondary antibody is raised against the species of the first antibody, such as anti-rabbit antibodies raised in a mouse.

Because the secondary antibody is enzyme linked, it becomes the signal generator. Once the substrate is added, the enzyme produces a detectable signal. As a result, the presence of the antigen can be measured indirectly through this antibody chain.

Why Use an Indirect ELISA Assay

At first glance, indirect ELISA may seem more complex than linking a marker directly to the antigen. However, this structure offers important advantages. Most importantly, it allows you to detect antibodies rather than antigens.

For example, if you want to determine whether someone has previously been exposed to a virus, indirect ELISA enables that measurement. The assay can detect antibodies produced by the body in response to infection. This flexibility explains why indirect ELISA is commonly used in immunology and diagnostics.

Where Indirect ELISA Fits Among ELISA Methods

Nick and Nigel also emphasize that indirect ELISA is just one configuration among many. While it is not always the most commonly used format, it serves as a foundation for understanding more advanced approaches. In fact, the episode closes with a preview of sandwich ELISA, which builds on many of the same principles and is often considered the most useful version in practice.

If you are learning how ELISA assays work, understanding indirect ELISA provides essential context for antibody detection strategies and assay design decisions.

Older woman at home checking a smartwatch while managing medications, illustrating remote monitoring medical devices in daily life

Connected health devices are multiplying fast. We examine the gap between remote monitoring’s promise and its reality.

Two people seated at a table holding handheld medical device prototypes, with text overlay reading "Is It Ready for a Human?" — MedDevice by Design episode on clinical prototypes for human use

Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.

Nick and Nigel each holding a different USPTO patent certificate, illustrating the difference between a design patent and a utility patent in a Bio Break episode

In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.

Mickey Urdea and Scott Phillips headshots for MedTech Unscripted exit strategy webinar

Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.